Orca-T对比传统异基因造血干细胞移植预防GVHD的3期随机试验
这项多中心3期随机试验纳入187例接受清髓性异基因造血干细胞移植的急性白血病或MDS成人患者,比较Orca-T联合他克莫司与常规移植联合他克莫司及甲氨蝶呤(Tac/MTX)预防GVHD的效果。
要点
- Orca-T显著提高1年cGFS(78.0% vs 38.4%),降低中重度cGVHD累积发生率(12.6% vs 44.0%)。
核心结论
- Orca-T达到主要终点,相比Tac/MTX预防方案显著改善无中重度慢性GVHD生存,应被视为低毒性的GVHD预防新治疗选择。
研究设计与样本
- 多中心3期随机试验,纳入187例接受清髓性预处理、HLA相合供者G-CSF动员外周血移植的急性白血病或骨髓增生异常综合征成人患者。
- 随机分配至Orca-T联合他克莫司组或常规移植物联合他克莫司及甲氨蝶呤(Tac/MTX)组。
- 主要终点为无中重度慢性GVHD生存(cGFS),采用分层log-rank检验。
- 试验注册号NCT05316701。
主要发现
- 1年cGFS为Orca-T组78.0% vs Tac/MTX组38.4%。
关键数值与推荐
- 1年cGFS:Orca-T组78.0%,Tac/MTX组38.4%。
临床怎么用
- 对于接受清髓性异基因造血干细胞移植的急性白血病或MDS成人患者,Orca-T联合他克莫司可作为低毒性GVHD预防的新选择。
- Orca-T方案与更少严重感染并发症和更低非复发死亡率相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To prevent graft-versus-host disease (GVHD) in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation (alloHSCT), a calcineurin inhibitor plus methotrexate is routinely used. Early phase studies suggested improved outcomes with Orca-T, an allogeneic T-cell immunotherapy that uses purified donor regulatory T cells to prevent GVHD with significantly less immunosuppression. This phase 3 trial randomized adult patients (N = 187) with acute leukemias or myelodysplastic syndrome undergoing myeloablative conditioning to receive either Orca-T with tacrolimus or a conventional allograft with tacrolimus and methotrexate (Tac/MTX), using granulocyte colony-stimulating factor-mobilized peripheral blood from HLA-matched donors. The primary end point was survival free from moderate-to-severe chronic GVHD (cGVHD; cGFS). Using a stratified log-rank test, cGFS was significantly higher in the Orca-T arm than in Tac/MTX (hazard ratio, 0.26; 95% confidence interval, 0.14-0.47; P< .001). One-year estimates were as follows: cGFS was 78.0% with Orca-T vs 38.4% with Tac/MTX; cumulative incidence of moderate-to-severe cGVHD was 12.6% with Orca-T and 44.0% with Tac/MTX (Gray test P< .001); overall survival was 93.9% with Orca-T vs 83.1% with Tac/MTX (P = .12); GVHD-free and relapse-free survival was 63.1% and 30.9% in the Orca-T and Tac/MTX arms (P< .001), respectively; nonrelapse mortality (NRM) was 3.4% with Orca-T vs 13.2% with Tac/MTX (P = .03). Orca-T met the primary end point of improved survival free from cGVHD compared with Tac/MTX prophylaxis and should be considered a new therapeutic option with low toxicity for GVHD prophylaxis. Moreover, significantly less toxicity was observed with Orca-T patients, including fewer serious infectious complications and less NRM. This trial was registered at www.clinicaltrials.gov as NCT05316701.
引用
- Meyer EH, Salhotra A, Gandhi AP, et al. Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial. Blood. 2026. PMID: 41385341. doi:10.1182/blood.2025031313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。